Alsner J - Search Results

1

Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer.

Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Agarwal R, et al. Among authors: alsner j. Clin Cancer Res. 2009 Jun 1;15(11):3654-62. doi: 10.1158/1078-0432.CCR-08-3293. Epub 2009 May 26. Clin Cancer Res. 2009. PMID: 19470724 Free PMC article.

2

Effects of light-guided nudges on health care workers' hand hygiene behavior.

Iversen AM, Hansen MB, Alsner J, Kristensen B, Ellermann-Eriksen S. Iversen AM, et al. Among authors: alsner j. Am J Infect Control. 2023 Dec;51(12):1370-1376. doi: 10.1016/j.ajic.2023.05.006. Epub 2023 May 18. Am J Infect Control. 2023. PMID: 37209875

3

The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma.

Horsman MR, Alsner J, Overgaard J. Horsman MR, et al. Among authors: alsner j. Acta Oncol. 1998;37(5):441-5. doi: 10.1080/028418698430386. Acta Oncol. 1998. PMID: 9831372

4

TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.

Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. Overgaard J, et al. Among authors: alsner j. Acta Oncol. 2000;39(3):327-33. doi: 10.1080/028418600750013096. Acta Oncol. 2000. PMID: 10987229

5

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.

Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Alsner J, et al. Clin Cancer Res. 2000 Oct;6(10):3923-31. doi: 10.1186/bcr109. Clin Cancer Res. 2000. PMID: 11051239 Free PMC article.

6

Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck.

Alsner J, Høyer M, Sørensen SB, Overgaard J. Alsner J, et al. Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):519-25. doi: 10.1016/s0360-3016(00)01489-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11173149

7

Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations.

Nordsmark M, Alsner J, Keller J, Nielsen OS, Jensen OM, Horsman MR, Overgaard J. Nordsmark M, et al. Among authors: alsner j. Br J Cancer. 2001 Apr 20;84(8):1070-5. doi: 10.1054/bjoc.2001.1728. Br J Cancer. 2001. PMID: 11308256 Free PMC article.

8

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.

Alsner J, Sørensen SB, Overgaard J. Alsner J, et al. Radiother Oncol. 2001 May;59(2):179-85. doi: 10.1016/s0167-8140(01)00301-2. Radiother Oncol. 2001. PMID: 11325447

9

Does variability in normal tissue reactions after radiotherapy have a genetic basis--where and how to look for it?

Andreassen CN, Alsner J, Overgaard J. Andreassen CN, et al. Among authors: alsner j. Radiother Oncol. 2002 Aug;64(2):131-40. doi: 10.1016/s0167-8140(02)00154-8. Radiother Oncol. 2002. PMID: 12242122 Review.

10

The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times.

Eriksen JG, Alsner J, Steiniche T, Overgaard J. Eriksen JG, et al. Among authors: alsner j. Radiother Oncol. 2005 Aug;76(2):135-42. doi: 10.1016/j.radonc.2005.05.004. Radiother Oncol. 2005. PMID: 16024113

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters